Filing Details

Accession Number:
0001562180-23-000222
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-05 16:06:21
Reporting Period:
2023-01-03
Accepted Time:
2023-01-05 16:06:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1590877 Regenxbio Inc. RGNX Biological Products, (No Disgnostic Substances) (2836) 471851754
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1700659 Steve Pakola C/O Regenxbio Inc.
9804 Medical Center Drive
Rockville MD 20850
Chief Medical Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-01-03 1,837 $22.68 15,313 No 4 F Direct
Common Stock Disposition 2023-01-03 3,138 $22.17 12,175 No 4 S Direct
Common Stock Acquisiton 2023-01-03 90,588 $0.00 102,763 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 F Direct
No 4 S Direct
No 4 A Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to buy) Acquisiton 2023-01-03 44,155 $0.00 44,155 $22.25
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
44,155 2033-01-03 No 4 A Direct
Footnotes
  1. Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021 and January 3, 2022. The number of shares withheld was determined on January 3, 2023 based on the closing price of the issuer's common stock on December 30, 2022.
  2. This transaction was effected pursuant to a Rule 10b5-1 trading plan.
  3. This transaction was executed in multiple trades at prices ranging from $22.0000 to $22.3800. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices atwhich the transaction was effected.
  4. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2024, January 1, 2025, January 1, 2026 and January 1, 2027 while the recipient provides continuous service to the Issuer.
  5. 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 48 months following January 3, 2024 while the optionee provides continuous service to the Issuer.